Tag
Briefings and ideas about AI drug discovery from AI podcast discussions and the research they cite, with links to the original sources.
Author Garrison Lovely argues that building AI to replace all human labor is a choice that can be stopped. He says medical benefits can be pursued directly through drug prizes and Warp Speed-style programs.
Box CEO Aaron Levie says shifting access permissions, like a lawyer walled off from rival matters, complicate training company knowledge into model weights. He wants a rubric on what to bake in and expects answers to vary by domain.
In an exploratory analysis of 42 lung-fibrosis patients, AI-designed drug rentosertib made protein aging clocks read about three years younger by week four. Mortality clocks didn't significantly shift at 60 mg, and the effect plateaued by week 12.
David Friedberg argued AI can screen a million protein ideas on computers to find ones that might reverse cell aging, without a full theory of the cell. The eye work he cited has reached a first safety trial in people, not restored sight.
GenBio's AIDO Cell simulates a human cell that remembers successive edits and drugs. For now it helps prioritize experiments in two cell lines; lab validation of its novel predictions is underway. A Moonshots panelist called it the end of medicine.
Merck and Moderna said personalized mRNA therapy intismeran autogene plus Keytruda beat Keytruda alone on melanoma recurrence-free and distant-metastasis-free survival in a 1,137-patient phase 3 interim analysis. No effect sizes were released.
NVIDIA reported $96.2 billion in quarterly revenue, up 106%, and guided to $108 billion. On Moonshots, Alexander Wissner-Gross asked how much of that demand NVIDIA financed itself; Dave Blundin argued it will stay sold out.
Bernie Sanders urged AI labs to honor their own safety commitments and pause development. On Moonshots, Emad Mostaque and others argued instead for genetic synthesis controls and threat detection; one panelist proposed monitoring all AI prompts.